REDESIGNING ANTIBODY DRUGS FROM THE GROUND UP
Xencor is expanding the therapeutic boundaries of monoclonal antibody and cytokine drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders. 20 programs are in clinical testing, and many more are in preclinical development.